Anti-Human CD28 Reference Antibody (Theralizumab, RUO) (HY422026)

Name: Anti-Human CD28 Reference Antibody (Theralizumab, RUO)
Brand: abinScience
SKU: HY422026
Price: 320 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HY422026
Description	Theralizumab (HY422026) is a research-grade recombinant antibody targeting CD28. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG4
Expression system	Mammalian cells
Clonality	Monoclonal
Target	CD28, TP44, T-cell-specific surface glycoprotein CD28
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P10747
Form	Liquid
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	TGN1412, TAB08, TAB-08, CD28-SuperMAB, 906068-56-2
Background	T-cell-specific surface glycoprotein CD28 is a ~25 kDa protein. Receptor that plays a role in T-cell activation, proliferation, survival and the maintenance of immune homeostasis. Functions not only as an amplifier of TCR signals but delivers unique signals that control intracellular biochemical events that alter the gene expression program of T-cells. Stimulation upon engagement of its cognate ligands CD80 or CD86 increases proliferation and expression of various cytokines in particular IL2 production in both CD4(+) and CD8(+) T-cell subsets. Mechanistically, ligation induces recruitment of protein kinase C-theta/PRKCQ and GRB2 leading to NF-kappa-B activation via both PI3K/Akt-dependent and -independent pathways. In conjunction with TCR/CD3 ligation and CD40L costimulation, enhances the production of IL4 and IL10 in T-cells. 1. Gimmi, CD. et al. (1991) Proceedings of the National Academy of Sciences of the United States of America 88, 6575-9. PMID: 1650475 2. Raab, M. et al. (1995) Proceedings of the National Academy of Sciences of the United States of America 92, 8891-5. PMID: 7568038 3. Skånland, SS. et al. (2014) The Biochemical journal 460, 399-410. PMID: 24665965 4. Collins, AV. et al. (2002) Immunity 17, 201-10. PMID: 12196291 5. Wu, H. et al. (2022) Structure (London, England : 1993) 30, 803-812.e5. PMID: 35397202 6. Kong, KF. et al. (2011) Nature immunology 12, 1105-12. PMID: 21964608 7. Blotta, MH. et al. (1996) Journal of immunology (Baltimore, Md. : 1950) 156, 3133-40. PMID: 8617933
Note	For research use only. Not suitable for clinical or therapeutic use.